注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Capricor Therapeutics Inc是一家生物技术公司。该公司专注于开发基于转化细胞和外质体的疗法和疫苗,用于治疗和预防广泛的疾病。该公司由细胞治疗计划组成,包括针对杜氏肌营养不良症的CAP-1002计划和针对冠状病毒(COVID-19)的CAP-1002和CAP-1002计划。该公司的主要候选药物CAP-1002是一种异基因心脏衍生细胞疗法。CAP-1002正在临床开发中,用于治疗Duchenne肌营养不良症和与2019冠状病毒疾病相关的细胞因子风暴。Capricor也在开发其exosome技术治疗平台。该公司致力于开发能够输送核酸(包括信使RNA(mRNA)和蛋白质)的外显体,以治疗或预防一系列疾病。CAP-1002细胞治疗项目启动了关键的第三阶段HOPE-3。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Frank Isaac Litvack | 67 | 2012 | Executive Chairman of the Board |
Linda Marbán | 60 | 2010 | Co-Founder, President, CEO & Director |
Eduardo Marbán | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Oscar Henry Mayer | - | - | Member of Scientific Advisory Board |
Barry J. Byrne | - | - | Member of Scientific Advisory Board |
Thomas Voit | - | - | Member of Scientific Advisory Board |
Eugenio Mercuri | - | - | Member of Scientific Advisory Board |
Earl M. Collier | 77 | 2013 | Independent Director |
David Brian Musket | 66 | 2013 | Independent Director |
Francesco Muntoni | - | - | Member of Scientific Advisory Board |
George W. Dunbar | 77 | 2013 | Independent Director |
Craig McDonald | - | - | Member of Scientific Advisory Board |
Michelle Eagle | - | - | Member of Scientific Advisory Board |
Pat Furlong | - | - | Member of Scientific Advisory Board |
Philip J. Gotwals | 61 | 2023 | Independent Director |
Paul Gisbert Auwaerter | 62 | 2023 | Independent Director |
Karimah Es Sabar | 66 | 2021 | Independent Director |
Michael Kelliher | 47 | 2023 | Independent Director |
Timothy R. Franson | 72 | 2023 | Member of the Scientific Advisory Board |
Michael Taylor | - | 2018 | Member of Scientific Advisory Board |
Suzanne Hendrix | - | 2023 | Member of Scientific Advisory Board |
Chet Villa | - | 2023 | Member of the Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核